Macrolides and airway inflammation in children

Area of Science:

• Pulmonology
• Infectious Diseases
• Pharmacology

Background:

• Macrolide antibiotics possess immunomodulatory properties utilized for over two decades in managing chronic inflammatory airway diseases.
• These properties include down-regulation of inflammation, enhanced mucus clearance, reduced bacterial virulence, and prevention of biofilm formation.

Purpose of the Study:

• To review the established and emerging clinical benefits of long-term macrolide therapy in various chronic inflammatory airway diseases.
• To highlight the efficacy in conditions such as cystic fibrosis, chronic sinobronchitis with nasal polyposis, and plastic bronchitis.

Main Methods:

• Review of existing literature on macrolide antibiotic use in chronic inflammatory airway diseases.
• Analysis of clinical outcomes including exacerbation rates, lung function, quality of life, and adverse events.

Main Results:

• Macrolides have demonstrated efficacy in reducing morbidity and mortality in diffuse panbronchiolitis and steroid-dependent asthma.
• Long-term macrolide therapy significantly reduces exacerbations and improves lung function and quality of life in pediatric cystic fibrosis patients.
• Clinical benefits are also observed in Japanese patients with chronic sinobronchitis, particularly those with nasal polyposis, and in some cases of plastic bronchitis.

Conclusions:

• Long-term macrolide therapy is a valuable treatment modality for several chronic inflammatory airway diseases, offering significant clinical benefits.
• The immunomodulatory effects of macrolides contribute to improved patient outcomes with a favorable safety profile at recommended dosages.